Breye Therapeutics raises €67.5 million in Series A led by Mission BioCapital and Novo Holdings to advance oral retinal disease treatments into Phase II trials.
Amount Raised
€67.5 Million
Round Type
Series A
CopenhagenBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaInvestors
Description
Breye Therapeutics, a clinical-stage biopharmaceutical company, successfully closed an over-subscribed €67.5 million Series A financing round co-led by Mission BioCapital and Novo Holdings. The round included participation from Sound Bioventures, the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, and Pappas Capital. Proceeds will fund advancement of danegaptide, a first-in-class oral treatment for Non-Proliferative Diabetic Retinopathy, into a Phase II clinical trial starting in 2027. The financing will also support development of the company's wider pipeline for retinal diseases, including a P2X7 receptor antagonist for intermediate age-related macular degeneration.
Quick answer
Breye Therapeutics raised €67.5 Million in a Series A round, dated September 29, 2026. Investors: Mission BioCapital, Pappas Capital, Modi Ventures, Catalyze Capital, Eifo, Ljungström family office, Sound Bioventures and Innovestor Life Science. Breye Therapeutics is based in Copenhagen, Capital Region Of Denmark, Denmark.
- How much did Breye Therapeutics raise?
- Breye Therapeutics raised €67.5 Million in a Series A round on September 29, 2026.
- Who invested in Breye Therapeutics?
- Mission BioCapital, Pappas Capital, Modi Ventures, Catalyze Capital, Eifo, Ljungström family office, Sound Bioventures and Innovestor Life Science are named as investors in this round.
- What does Breye Therapeutics do?
- Breye Therapeutics is a clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases.
- Where is Breye Therapeutics based and how big is it?
- Breye Therapeutics is based in Copenhagen, Capital Region Of Denmark, Denmark. Fundz records about 2 employees.
Source: Fundz verified event record.
Who else raised in Therapeutics and Pharmaceutical around the same time
Companies in the same sectors as Breye Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Quanta Therapeutics raised an undisclosed amount (Series D) on October 24, 2026.
- Disc raised $422M (Post-IPO Equity) on October 20, 2026.
- Acta Pharmaceuticals raised $24M (Seed) on October 15, 2026.
- Os Therapies raised $7.2M on October 15, 2026.
- Ensho Therapeutics raised $7.3M on October 2, 2026.
- Orvida Pharma raised an undisclosed amount on September 15, 2026.
Who to call at Breye Therapeutics, and when
A new round usually means Breye Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Breye Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Breye Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Breye Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Breye Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansBreye Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.